Halia Therapeutics Inc. and Canary Speech Inc. have established a collaboration in Alzheimer’s disease. This collaboration leverages Canary Speech’s artificial intelligence (AI) vocal biomarker platform, which utilizes advanced AI algorithms to analyze subtle changes...

Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024 'Investors and entrepreneurs also are wrestling with questions such as the impact of the 2022 Inflation Reduction Act, which enabled Medicare to negotiate prices of certain medications, said...

January 11th, 2024 Author: Danny Sullivan Dr. David Bearss was featured in Longevity.Technology discussing Halia Therapeutics moving into multiple Phase 2 trials for chronic inflammation and whether the company may have created a ‘longevity drug.’ Fresh from...

Alternative Funding Strategies to Discuss at JPM https://www.youtube.com/watch?v=c3PAvs5gwFE The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that...

One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing...

Starting a company is interesting. I’m a scientist by training and have often considered myself the world’s most reluctant entrepreneur. Halia Therapeutics is the sixth company I’ve started, but most of the time, I still think of myself as the guy who used...

David Bearss’ passion for drug discovery has guided his noteworthy career as a dynamic leader who integrates scientific and business interests to deliver new medicines to patients. That passion is still evident today as he gives back to the industry he loves, making a difference with bold initiatives to improve health and change the face of Utah’s life sciences ecosystem.

Halia Therapeutics has a new lab in Lehi and believes it is on the forefront of research to target chronic inflammation to treat neurodegeneration and inflammatory diseases.

Thanks to Salt Lake City’s FOX 13 News for attending and reporting on Halia Therapeutics’ grand opening. This report aired August 23, 2013.

Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and neurological diseases.